Evonik

Abstract Mucopolysaccharidosis type I (MPS-I) is a rare, multisystemic lysosomal storage disease (LSD) caused by mutations in the IDUA gene, which encodes...

Abstract Purpose: To formulate enteric-coated osmotic tablets for colon-targeted delivery of hydrocortisone. Methods: Nine core tablet batches were prepared with...

Why Evonik established a presence in Vancouver and Cambridge: to be close to cutting-edge science, innovative startups, and the next...

Abstract Purpose Simvastatin (SIM) is a widely prescribed lipid-lowering agent; however, its clinical efficacy is hindered by poor aqueous solubility...

Abstract Objectives: A customizable 3D-bioprinted core-in-shell platform was developed for time-dependent oral colon delivery of live microorganisms. The system conveyed Lacticaseibacillus paracasei as...

Abstract Despite their widely recognized performance-related benefits, nanosuspensions (NSs) present major challenges, mainly due to their poor stability during storage....

Abstract Background: An increasing number of commercially available drug substances and bioactive ingredients are characterized by poor flowability. Inadequate flow...

Press Release Evonik has received two Pharma Excipients Awards at CPHI China 2026 in Shanghai. The company won the “Market Impact”...

Abstract The physical stability of salbutamol amorphous solid dispersion (ASD) pharmaceutical tablets, manufactured via a novel strategy employing liquid drug...

Abstract Background: Existing therapies for xerostomia are primarily symptomatic, providing temporary mucosal hydration without addressing underlying pathological changes in the...